The U.S. pharmaceutical giant, Pfizer announced today a definitive agreement to acquire King Pharmaceuticals. The deal provides for the control of King, a consideration of $ 3.6 billion in cash ($ 14.25 per share).
This is an assessment that implies, emphasizes the note today that Pfizer, a premium of about 40% on the closure of King at the end of the session yesterday and about 46% on average prices last month.
Both boards of the companies involved have approved the merger deal that would
Tidak ada komentar:
Posting Komentar